Combination therapies are certainly where it’s at for Merck and Keytruda at the moment, across all indications. This out of the US this morning:
https://www.fiercepharma.com/marketing/merck-s-keytruda-blockbuster-frontier-first-class-fda-approval-post-surgery-adjuvant?oly_enc_id=2993B0391467A3V
Ann: Phase II TACTI-002 trial recruitment successfully completed, page-5
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.5¢ |
Change
-0.015(4.55%) |
Mkt cap ! $450.9M | |||
| Open | High | Low | Value | Volume |
| 32.5¢ | 32.5¢ | 31.0¢ | $636.1K | 2.031M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 196083 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 84768 | 10 |
View Market Depth
| Last trade - 12.06pm 18/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |